INFANT Research Centre

Permanent URI for this community

https://hdl.handle.net/10468/4183

INFANT A research centre focused entirely on pregnancy, birth and early childhood. Hosted at University College Cork (UCC), Cork, Ireland, The Irish Centre for Maternal and Child Health Research has local impact with a global reach. INFANT is answering the international need for research and innovation to improve health outcomes for mothers and babies. Across pregnancy, birth, infancy and childhood, INFANT is solving challenges through its key research themes

Visit the INFANT Centre website: www.infantcentre.ie/

Browse

Browsing INFANT Research Centre by Author "Alfirevic, Zarko"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial
    (Elsevier B.V., 2018) Sharp, Andrew; Cornforth, Christine; Jackson, Richard; Harrold, Jane; Turner, Mark A.; Kenny, Louise C.; Baker, Philip N.; Johnstone, Edward D.; Khalil, Asma; von Dadelszen, Peter; Papageorghiou, Aris T.; Alfirevic, Zarko; National Institute for Health Research; Medical Research Council
    Background: Severe early-onset fetal growth restriction can lead to a range of adverse outcomes including fetal or neonatal death, neurodisability, and lifelong risks to the health of the affected child. Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the actions of nitric oxide, which leads to vasodilatation of the uterine vessels and might improve fetal growth in utero. Methods: We did this superiority, placebo-controlled randomised trial in 19 fetal medicine units in the UK. We used random computer allocation (1:1) to assign women with singleton pregnancies between 22 weeks and 0 days' gestation and 29 weeks and 6 days' gestation and severe early-onset fetal growth restriction to receive either sildenafil 25 mg three times daily or placebo until 32 weeks and 0 days' gestation or delivery. We stratified women by site and by their gestational age at randomisation (before week 26 and 0 days or at week 26 and 0 days or later). We defined fetal growth restriction as a combination of estimated fetal weight or abdominal circumference below tenth percentile and absent or reversed end-diastolic blood flow in the umbilical artery on Doppler velocimetry. The primary outcome was the time from randomisation to delivery, measured in days. This study is registered with BioMed Central, number ISRCTN 39133303. Findings: Between Nov 21, 2014, and July 6, 2016, we recruited 135 women and randomly assigned 70 women to sildenafil and 65 women to placebo. We found no difference in the median randomisation to delivery interval between women assigned to sildenafil (17 days [IQR 7–24]) and women assigned to placebo (18 days [8–28]; p=0·23). Livebirths (relative risk [RR] 1·06, 95% CI 0·84 to 1·33; p=0·62), fetal deaths (0·89, 0·54 to 1·45; p=0·64), neonatal deaths (1·33, 0·54 to 3·28; p=0·53), and birthweight (−14 g,–100 to 126; p=0·81) did not differ between groups. No differences were found for any other secondary outcomes. Eight serious adverse events were reported during the course of the study (six in the placebo group and two in the sildenafil group); none of these were attributed to sildenafil. Interpretation: Sildenafil did not prolong pregnancy or improve pregnancy outcomes in severe early-onset fetal growth restriction and therefore it should not be prescribed for this indication outside of research studies with explicit participants' consent.
  • Thumbnail Image
    Item
    STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials
    (BioMed Central, 2017) Pels, A.; Kenny, Louise C.; Alfirevic, Zarko; Baker, Philip N.; von Dadelszen, Peter; Gluud, C.; Kariya, C. T.; Mol, B. W.; Papageorghiou, A. T.; van Wassenaer-Leemhuis, A. G.; Ganzevoort, W.; Groom, K. M.; Medical Research Council; National Institute for Health Research; ZonMw; Health Research Board; Canadian Institutes of Health Research; Nurture Foundation for Reproductive Research; Cure Kids; Health Research Council of New Zealand; Copenhagen Trial Unit
    Background: Severe, early-onset fetal growth restriction due to placental insufficiency is associated with a high risk of perinatal mortality and morbidity with long-lasting sequelae. Placental insufficiency is the result of abnormal formation and function of the placenta with inadequate remodelling of the maternal spiral arteries. There is currently no effective therapy available. Some evidence suggests sildenafil citrate may improve uteroplacental blood flow, fetal growth, and meaningful infant outcomes. The objective of the Sildenafil TheRapy In Dismal prognosis Early onset fetal growth Restriction (STRIDER) collaboration is to evaluate the effectiveness of sildenafil versus placebo in achieving healthy perinatal survival through the conduct of randomised clinical trials and systematic review including individual patient data meta-analysis. Methods: Five national/bi-national multicentre randomised placebo-controlled trials have been launched. Women with a singleton pregnancy between 18 and 30 weeks with severe fetal growth restriction of likely placental origin, and where the likelihood of perinatal death/severe morbidity is estimated to be significant are included. Participants will receive either sildenafil 25 mg or matching placebo tablets orally three times daily from recruitment to 32 weeks gestation. Discussion: The STRIDER trials were conceived and designed through international collaboration. Although the individual trials have different primary outcomes for reasons of sample size and feasibility, all trials will collect a standard set of outcomes including survival without severe neonatal morbidity at time of hospital discharge. This is a summary of all the STRIDER trial protocols and provides an example of a prospectively planned international clinical research collaboration. All five individual trials will contribute to a pre-planned systematic review of the topic including individual patient data meta-analysis